|
Notes |
% change |
Unaudited six months ended 30 June 2026 R’000 |
Re-presented* Unaudited six months ended 30 June 2025 R’000 |
Audited year ended 31 December 2025 R’000 |
||
|
Healthcare services revenue |
3.1 |
2 432 566 |
2 359 291 |
4 067 007 |
||
|
Healthcare services operating costs |
(5.9) |
(2 253 348) |
(2 127 289) |
(3 571 133) |
||
|
IFRS 16: Lease reversals |
42 508 |
42 104 |
80 991 |
|||
|
Healthcare services operating profit |
(19.1) |
221 726 |
274 106 |
576 865 |
||
|
Healthcare retail revenue |
(16.0) |
1 127 221 |
1 342 546 |
3 379 833 |
||
|
Healthcare retail cost of sales |
18.4 |
(944 696) |
(1 157 093) |
(2 171 506) |
||
|
Healthcare retail operating costs |
18.8 |
(122 093) |
(150 387) |
(1 106 409) |
||
|
Healthcare retail operating profit |
72.3 |
60 432 |
35 066 |
101 918 |
||
|
Total healthcare operating profit (including lease reversals) |
(8.8) |
282 158 |
309 172 |
678 783 |
||
|
Dividends received |
180 |
143 |
– |
|||
|
Fair value loss |
– |
– |
(89) |
|||
|
Fair value loss on investment property |
– |
– |
(830) |
|||
|
Other income |
1 |
17 |
50 |
|||
|
Reversal of impairment of loans |
– |
33 |
– |
|||
|
Impairment of right-of-use assets |
– |
– |
(1 498) |
|||
|
Impairment of property and equipment |
– |
– |
(1 301) |
|||
|
Impairment of goodwill |
– |
– |
(810 935) |
|||
|
Reversal of impairment of property and equipment |
1 |
– |
– |
|||
|
Impairment of intangible assets |
– |
– |
(11 180) |
|||
|
Profit on sale of subsidiary |
– |
5 101 |
5 101 |
|||
|
Net finance and investment income/(loss) |
161 |
(16 612) |
(13 059) |
|||
|
– Finance and investment income |
31 959 |
19 666 |
62 445 |
|||
|
– Finance costs: Lease liabilities |
(4 904) |
(7 205) |
(13 273) |
|||
|
– Finance costs |
(26 894) |
(29 073) |
(62 231) |
|||
|
Share-based award (expense)/income |
(2 115) |
(12 551) |
2 564 |
|||
|
Share of profits from associates and joint ventures |
1 285 |
2 600 |
6 663 |
|||
|
Profit/(loss) before depreciation and amortisation |
(2.2) |
281 671 |
287 903 |
(145 731) |
||
|
Depreciation |
4.5 |
(59 463) |
(62 238) |
(123 999) |
||
|
Right-of-use assets depreciation |
12.4 |
(27 532) |
(31 444) |
(60 090) |
||
|
Amortisation of intangible assets |
21.3 |
(83 233) |
(105 730) |
(202 081) |
||
|
Profit/(loss) before taxation |
25.9 |
111 443 |
88 491 |
(531 901) |
||
|
Taxation expense |
(27 729) |
(39 620) |
(114 046) |
|||
|
Profit/(loss) for the period from continuing operations |
71.3 |
83 714 |
48 871 |
(645 947) |
||
|
(Loss)/profit from discontinued operations net of tax |
(12 920) |
57 783 |
(613 279) |
|||
|
Profit/(loss) for the period |
(33.6) |
70 794 |
106 654 |
(1 259 226) |
||
|
Other comprehensive income/(loss) |
6 270 |
(5 555) |
(10 886) |
|||
|
Comprehensive net income/(loss) for the period |
(23.8) |
77 064 |
101 099 |
(1 270 112) |
||
|
Attributable to: |
||||||
|
Equity holders of the Parent |
72 112 |
91 509 |
(1 285 096) |
|||
|
Non-controlling interest |
4 952 |
9 590 |
14 984 |
|||
|
77 064 |
101 099 |
(1 270 112) |
| * | The Supplementary information operating performance (non-IFRS measure) has been re-presented to separately disclose discontinued operations that were previously included in continuing operations for comparative periods presented (Refer to Note 6 for further details). |